Janney Capital Initiates Coverage on Insys Therapeutics Inc(NASDAQ:INSY). The shares have been rated Buy. The rating by Janney Capital was issued on Apr 14, 2016.
In a different note, On Mar 9, 2016, JMP Securities said it Maintains its rating on Insys Therapeutics Inc. In the research note, the firm Lowers the price-target to $38.00 per share. The shares have been rated ‘Market Outperform’ by the firm. On Feb 24, 2016, Jefferies said it Maintains its rating on Insys Therapeutics Inc. In the research note, the firm Lowers the price-target to $36.00 per share. The shares have been rated ‘Buy’ by the firm.
Insys Therapeutics Inc (INSY) made into the market gainers list on Mondays trading session with the shares advancing 5.03% or 0.72 points. Due to strong positive momentum, the stock ended at $15.04, which is also near the day’s high of $15.25. The stock began the session at $14.42 and the volume stood at 5,90,540 shares. The 52-week high of the shares is $46.17 and the 52 week low is $12.5. The company has a current market capitalization of $1,076 M and it has 7,15,10,190 shares in outstanding.
Insys Therapeutics Inc(INSY) last announced its earnings results on Feb 23, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $91.14M. Analysts had an estimated revenue of $91.04M. Earnings per share were $0.36. Analysts had estimated an EPS of $0.29.
Several Insider Transactions has been reported to the SEC. On Mar 7, 2016, Patrick Fourteau (director) sold 15,000 shares at $18.22 per share price.Also, On Mar 4, 2016, Theodore H Stanley (director) sold 20,000 shares at $18.11 per share price.On Nov 18, 2015, John N Kapoor (CEO) purchased 5,000 shares at $29.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.